We examine the need for professional intervention to ensure patients reap the full benefits of CBD use
A few years ago, CBD was a substance many hadn’t even heard of.
Fast forward to 2020, and according to the Alphagreen report published in May, almost eight million Britons have purchased CBD products.
The report also identified an increase of sales between March to May 2020 due to COVID-19, with sales expected to continue to rise throughout the remainder of the year.
But, with so many people trying CBD products for the first time, it raises the question of what exactly are people taking and are they taking it correctly?
Most CBD users are not even able to recognise the difference between CBD products and medical cannabis.
Consumer education is vital to ensure people fully understand what they are taking, how to take it and how it will benefit them.
Over 42% of cannabidiol users are using CBD to cope with pain, followed by insomnia (21%) and stress relief (19%). What is the source here?
Similarly, according to CBD Intel , 38% of German users were taking CBD to combat pain relief and 32% in France.
We know that there are a variety of different CBD products on the market, but the Centre for Medical Cannabis has found that only a third of these products are safe in accordance with declared cannabinoid content.
At Endoverse it is our priority to provide consumers with reliable and evidence-based information.
Today there are over three million CBD users seeking medical benefits from using it.
At Endoverse we believe many can benefit from CBD usage – but only with the proper professional support and guidance.
It is also important to note, there are many ways to modulate the endocannabinoid system (ECS) without the use of phytocannabinoids. This is increasingly important due to the levels of CBD food uncertainty within CBD products.
The ECS is involved in most long-term health conditions such as pain, insomnia, anxiety, but also in diabetes, cardiovascular, autoimmune diseases and cancer.
Market driven interest in cannabidiol is often related with misunderstanding and misinterpretation of related scientific evidence.
Clients are convinced that they should boost their ECS. Often clinical endocannabinoid deficiency syndrome (CEDS) is diagnosed, however this syndrome is still to be explored further.
Moreover, CEDS is related to a minority of clients that can benefit from boosting their ECS, while the majority of their health conditions are actually related to ECS overactivity.
We need as many professionals as possible to be trained in ECS management and to support clients seeking health benefits from cannabidiol.
As the ECS is strongly involved in homeostasis regulation, as well as related to food intake and metabolism, especially metabolism of the fatty acids, dietitians are one of the best first line professionals for this kind of support.
Together with lifestyle impacts on ECS and the potential high importance of Metabolic syndrome ethiology, there is a huge space for GPs and nurses, but also for complementary and alternative care providers in the wellness and fitness fields.
Endocannabinology – Balance Medicine – provides a holistic framework for the process of achieving ECS balance at an individual level.
At first glance, we are repeating generally well-known recommendations regarding diet, exercise, stress reduction and other lifestyle interventions. This may appear that we are not differing from other holistic remedies or person-oriented approaches.
But, there is one key difference – we are aware of the strong impact of the ECS activation in reward seeking behaviour, responsible for food (and other) cravings, and we are able to target our interventions to influence this behavioural loop that prevents clients from making effective changes to their lifestyle.
The resulting changes in health conditions makes Balance Medicine a potentially very powerful tool for clinicians as well as for clients.